We are international
Donate
• IMF TV TEXT SIZE   
#Ask Dr. Durie

ask_dr_durie_banner

 

Have a question? Submit it to AskDrDurie@myeloma.org!
 

facebook
googleplus
twitter
youtube


#AskDrDurie is the IMF’s weekly web series, hosted by IMF Chairman Dr. Brian Durie, which answers questions of broad audience interest about myeloma. If you have a question that might be of interest to the general myeloma community, please send it to AskDrDurie@myeloma.org for consideration. Thank you!

Our archives are brimming with useful information directed at - and asked by - patients, caregivers, and other interested parties... so please watch the episodes below, and share them as much as possible so that others may benefit!


 

 

 

#Ask Dr. Durie
    next      view all

02.26.15   What is the typical speed of improvement in the Freelite and protein levels with myeloma treatment?

In this new episode of #AskDrDurie, IMF Chairman Dr. Brian Durie discusses how fast a myeloma patient would see improvement in both Freelite and protein levels with treatment such as three-drug combinations.


02.19.15   What are some treatment options for the t(4;14) abnormality?

In this episode of #AskDrDurie, IMF Chairman Dr. Brian Durie discusses treatment options available for those myeloma patients with the t(4;14) abnormality, including IMiDs, next-generation proteasome inhibitors, novel combination therapies, and autologous stem cell transplants.


02.12.15   What does ‘dysplasia’ mean within the bone marrow report?

In this episode of the IMF’s weekly web series, #AskDrDurie, IMF Chairman Dr. Brian Durie explains what dysplasia means when it shows up on a bone marrow report.


02.05.15   Should gadolinium be used as part of MRI testing?

In this episode of #AskDrDurie, IMF Chairman Dr. Brian Durie discusses the use of gadolinium in MRI testing, specifically for patients with abnormal kidney function.


01.29.15   What is the M protein?

This week, Dr. Brian Durie of the IMF answers a patient's question about the M protein and how levels are affected by time and treatment.


01.22.15   If bone density is low, does that mean myeloma is present?

In this week's episode of #AskDrDurie, IMF Chairman Dr. Brian Durie answers a patient's question about levels of bone density and how they connect to myeloma.


01.15.15   What is the 17p deletion?

In this week’s episode of #AskDrDurie Dr. Brian Durie discusses the importance of the 17p deletion chromosome abnormality when remission has been achieved.


01.08.15   #AskDrDurie: What’s new with the Black Swan Research Initiative®?

In the first episode of the new year, Dr. Brian Durie of the IMF looks back on the progress of a signature project, the Black Swan Research Initiative® to discuss major accomplishments in 2014.


12.18.14   #AskDrDurie: What does IMWG’s new diagnostic criteria mean for myeloma patients?

In this episode of #AskDrDurie, Dr. Brian Durie talks about the new diagnostic guidelines and tests that can be used to diagnose myeloma early, before CRAB features have emerged. These criteria have been published in a new publication available on myeloma.org.


12.10.14   #AskDrDurie: Why wasn’t panobinostat approved?

In this episode of #AskDrDurie, Dr. Brian Durie of the IMF answers a  patient's question about why the recent FDA ODAC hearing rejected the use of new drug panobinostat for myeloma. He also discusses other HDAC inhibitors that are currently in development.


    next      view all